New test for mysterious metabolic diseases developed at Stanford/Packard

February 11, 2009

STANFORD, Calif. -Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism.

Mitochondrial disorders can cause organ failure, seizures, stroke-like episodes and premature death. The diseases-more than three dozen in total-arise from genetic errors of the mitochondria, the cell structures that process oxygen and turn food molecules into useable energy. Mitochondrial disorders affect one in 4,000 kids and one in 8,500 adults. They are difficult to diagnose, and no treatments or cures exist.

But that could soon change. A team at Stanford and Lucile Packard Children's Hospital has discovered a biological marker they can use to monitor the diseases. The finding will enable researchers to hunt for treatments and help physicians check patients' status before health crises erupt. The research was published online Feb. 9 in the Proceedings of the National Academy of Sciences.

"When a car engine doesn't work right, it smokes," said senior study author Greg Enns, MB, ChB, who is professor of pediatrics at Stanford University School of Medicine and director of the biochemical genetics program at Packard. "What we looked for is, in essence, biochemical smoke."

Like a car engine, when mitochondria are not burning fuel cleanly, they kick out nasty gunk. Defective mitochondria produce large quantities of oxygen free radicals-highly reactive molecules that damage DNA and cell structures. Comparing patients who have a mitochondrial disorder with healthy people in the control group, Enns' team searched for signs that free radicals overtax patients' natural antioxidant defense systems. And they found it.

"Even when these patients are coming into the clinic looking pretty healthy, they have evidence of extra metabolic stress," Enns said, noting the findings were surprising because none of the patients were in the midst of a health crisis such as organ failure when blood samples were taken. It is the first time such signs have been uniformly shown in the blood of patients across a wide range of mitochondrial disorders, he added.

The team saw that levels of glutathione, the body's primary antioxidant, were significantly reduced in white blood cells from the 20 mitochondrial disease patients in the study. The observation means patients' antioxidant defenses were indeed depleted. Glutathione was also diminished in nine patients with organic acidemias, another group of metabolic diseases that researchers think may be associated with aberrant mitochondrial function.

A second finding gave the researchers a big hint about where to hunt for treatments. Patients taking antioxidant supplements did not have depleted glutathione, they found. Scientists have long suspected antioxidants such as vitamin C and vitamin E might help patients with mitochondrial disease or organic acidemias, and doctors sometimes suggest the supplements to their patients. But no one has been able to test whether they work.

"As a clinician, one of the most frustrating things has been not being sure if supplements are doing any good," said Enns. "Now we're able to take a baseline blood reading and see 'before' and 'after' snapshots."

William Craigen, MD, PhD, the director of the metabolic clinic at Texas Children's Hospital, called this finding "the beginning of insight into the mechanisms of mitochondrial disease." Craigen, who is also medical director for the mitochondrial diagnostic lab at Baylor College of Medicine, was not involved in the Stanford study. "This new research provides an opportunity to start treating a heterogeneous group of diseases in a single fashion, with a simple and easy-to-administer treatment, potentially improving patients' long-term outcomes," he added.

Glutathione measurements could also help diagnose patients, Enns said, by giving physicians a clear indication that something is awry in the mitochondria. Genetic and molecular tests have already led to increases in the number of diagnoses, but the diagnosis is still difficult to pin down.

The method Enns' team used to measure glutathione, called high-dimensional flow cytometry, has limitations: it requires very fresh blood samples, uses expensive equipment only available in research labs, and provides relative rather than absolute glutathione measurements. Now that the team knows what metabolic change to look for, they're working to develop a more broadly applicable measurement technique.

And glutathione measurements could help scientists unravel other disease mysteries, too. "You name the disease, you can postulate mitochondrial involvement," Enns said. "It's been proposed for everything from poor vision to hearing loss, kidney disease, liver disease, autism spectrum disorders, diabetes, Alzheimer disease, cancers. Our work could lead to research on therapies for a broad range of disorders."

Stanford University Medical Center

---

---

	Mitochondrial Disorders: Biochemical and Molecular Analysis (Methods in Molecular Biology, Vol. 837) by Lee-Jun C. Wong Ph.D. (Editor) Due to the complexity of the mitochondrial system and the myriad genes involved in their function, the clinical manifestations of mitochondrial diseases are remarkably variable and heterogeneous. The laboratory and clinical methodologies used to evaluate dysfunction may vary widely, and thusly a systematic presentation of the numerous protocols that are applied to the assessment of these clinically and genetically heterogeneous disorders has proven to be essential.  Mitochondrial Disorders: Biochemical and Molecular Analysis strives to fill this need with a collection of key protocols provided by leading experts in the field.  Beginning with overviews of complexity of mitochondrial and nuclear genome disorders, the book continues with a section devoted to current biochemical protocols...
	Mitochondrial Disorders Caused by Nuclear Genes by Lee-Jun C. Wong (Editor) Mitochondrial cytopathies are mutations in the inherited maternal mitochondrial genome, or the nuclear DNA-mutation. Mitochondrial respiratory chain disorders (RCD) are a group of genetically and clinically heterogeneous diseases, due to the fact that protein components of the respiratory chain are encoded by both mitochondrial and nuclear genomes and are essential in all cells.  In addition, the biogenesis, structure and function of mitochondria, including DNA replication, transcription, and translation, all require nuclear encoded genes.  Since mitochondria are present in every cell, every tissue, mitochondrial disorder usually affects multiple organs.
	Living Well With Mitochondrial Disease: A Handbook for Patients, Parents, and Families by Cristy Balcells (Author) LIVING WELL WITH MITOCHONDRIAL DISEASE helps make sense of mitochondrial disease (Mito), an overwhelming and complex group of diagnoses that has grown exponentially in recent years. The most common of all metabolic disorders, thought to be more common than cystic fibrosis and broader-reaching than most genetic diseases, Mito can affect babies, children, and teens from birth or at any point during their development. Previously healthy adults, as well as adults with a history of unexplained fatigue, are increasingly receiving a Mito diagnosis. Some children with autism spectrum disorders who have medical issues such as digestive difficulties and fatigue are also being identified as having a mitochondrial disorder. This guide is the first book about Mito written for patients and their...
	Mitochondrial Inhibitors and Neurodegenerative Disorders (Contemporary Neuroscience) by Paul R. Sanberg (Editor), Hitoo Nishino (Editor), Cesario V. Borlongan (Editor) Respected investigators from around the world critically review what is known about the role of mitochondrial inhibitors in cell death and the onset of neurodegeneration. These distinguished researchers-many pioneers in the field-detail the symptomology, origin, and chemistry of mitochondrial toxins, and discuss animal models of human diseases related to abnormal mitochondrial function. The emphasis on 3-NP and its ability to replicate the cellular, anatomical, and behavioral alterations seen in Huntington's disease demonstrate that mitochondrial inhibitors play an important role in the etiology of central nervous system disorders. The book also discusses recent therapeutic modalities aimed at rescuing the central nervous system from abnormal mitochodrial functioning. With its timely,...
	Mitochondrial Disorders by Claude Desnuelle (Author), S. Di Mauro (Contributor) The concept of mitochondrial diseases originated in 1962 with the description by Luft and coworkers of a patient with nonthyroidal hypermetabolism due to loose coupling of oxidation and phosphorylation in muscle mitochondria. Over the following quarter of a century, thanks to W. King Engel's "ragged-red fibres" as convenient markers for mitochondrial pathology, numerous papers described clinical, morphological, and biochemical features of "mitochondrial myopathies". In 1988 the discovery of mutations in mitochondrial DNA led to an explosive expansion of research into mitochondrial disorders. Throughout the 1990s the rapid identification of multiple mitochondrial gene defects associated with clinically diverse disorders has left practitioners puzzled about diagnosing such heterogeneous...
	Mitochondrial Dysfunction in Neurodegenerative Disorders by Amy Katherine Reeve (Editor), Kim Jennifer Krishnan (Editor), Michael R. Duchen (Editor), Doug M Turnbull (Editor) As age related diseases increase in prevalence and impact more significantly on medical resources it is imperative to understand these diseases and the mechanisms behind their progression. New research has stimulated a growing interest in mitochondrial involvement in neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis and the mechanisms which lead from mitochondrial dysfunction to neurodegeneration. Mitochondrial Dysfunction in Neurodegenerative Disorders brings together contributions from leaders in the field internationally on the various ways in which mitochondrial dysfunction contributes to the pathogenesis of these diseases, guiding the reader through the basic functions of mitochondria and the mechanisms that lead to their...
	Mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS): a mitochondrial disorder presents as fibromyalgia.(Case Report): An article from: Southern Medical Journal by Rowena A. DeSouza (Author), Raul J. Cardenas (Author), Tekisha U. Lindler (Author), Francisco A. De la Fuente (Author), Francisco J. Mayorquin (Author), David S. Trochtenberg (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on May 1, 2004. The length of the article is 2446 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS): a mitochondrial disorder presents as fibromyalgia.(Case Report) Author: Rowena A. DeSouza Publication: Southern Medical Journal (Refereed) Date: May 1, 2004 Publisher: Southern Medical Association Volume: 97 Issue: 5 Page: 528(4) Distributed by Thomson...
	Mitochondrial disorders: a clinician's primer. (Clinical Practice).: An article from: MedSurg Nursing by Mindy B. Tinkle (Author), Frank Castora (Author) This digital document is an article from MedSurg Nursing, published by Jannetti Publications, Inc. on February 1, 2002. The length of the article is 3035 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. From the author: Mitochondrial disorders represent an extremely challenging set of conditions, partly due to the complexities of the mitochondrial genetic system. Nurses must be prepared with knowledge about genetic conditions so that they can participate fully in early identification of affected individuals and assist them in accessing the most current genetic diagnostic and treatment therapeutics. This...
	Repligen licenses patent rights for treatment of mitochondrial disorders and purine autism.(Brief Article): An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on December 1, 2000. The length of the article is 829 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Repligen licenses patent rights for treatment of mitochondrial disorders and purine autism.(Brief Article) Publication: BIOTECH Patent News (Newsletter) Date: December 1, 2000 Publisher: Biotech Patent News Volume: 14 Issue: 12 Page: NA Article Type: Brief Article Distributed by Thomson...
	Mitochondrial disorder aggravated by propranolol.(Case Report)(medical research)(includes related article "Key Points" and statistical tables): An article from: Southern Medical Journal by Josef Finsterer (Author), Ellen Gelpi (Author) This digital document is an article from Southern Medical Journal, published by Thomson Gale on July 1, 2006. The length of the article is 2185 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Mitochondrial disorder aggravated by propranolol.(Case Report)(medical research)(includes related article "Key Points" and statistical tables) Author: Josef Finsterer Publication: Southern Medical Journal (Magazine/Journal) Date: July 1, 2006 Publisher: Thomson Gale Volume: 99 Issue: 7 Page: 768(4) Distributed by Thomson...